PROTEA BIOSCIENCES GROUP, INC. (OTCMKTS:PRGB) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02.
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On June 9, 2017, Maged Shenouda resigned as a Director of Protea
Biosciences Group, Inc. (the Company). To the knowledge of the
Companys executive officers, the resignations of Mr. Shenouda was
not the result of any disagreement by Mr. Shenouda with the
Company on any matter related to the Companys operations,
policies or practices.
About PROTEA BIOSCIENCES GROUP, INC. (OTCMKTS:PRGB)
Protea Biosciences Group, Inc. is a molecular information company. The Company is engaged in developing and commercializing life science technologies, products and services to identify the molecules that are produced by living cells and all life forms. It also offers a platform technology, Laser Ablation Electrospray Ionization (LAESI), which enables the direct analysis, mapping and display of molecular information in living cells and tissue samples. The Company’s commercial development is centered in three business lines: Molecular Information Services, LAESI Instruments, Software and Consumables, and Molecular Diagnostics and Clinical Research. Its services enable the identification and quantitation of both small molecules (lipids and metabolites) and large molecules (proteins) and the services portfolio, inclusive of mass spectrometry imaging (MSI), proteomics, metabolomics, lipidomics and bioinformatics. Its clients include pharmaceutical, chemical and biotechnology companies.
